Allurion Secures FDA Nod for Smart Capsule, Eyes US Market Expansion

TL;DR

**ALUR's FDA approval is a game-changer, positioning them for significant growth in the massive US weight loss market, making it a strong buy.**

AI Summary

Allurion Technologies, Inc. (ALUR) is pioneering metabolically healthy weight loss with its Allurion Program, featuring the Allurion Smart Capsule, the world's first and only swallowable, Procedureless™ intragastric balloon. The company reported that over 200,000 patients have been treated commercially in over 50 countries outside the U.S. The Allurion Program also includes the Allurion Virtual Care Suite (VCS) with AI-powered remote patient monitoring tools and a proprietary behavior change program. On February 20, 2026, the FDA granted PMA approval for the Allurion Gastric Balloon System (AGBS) for adults with a BMI between 30 kg/m2 and 40 kg/m2. The company raised approximately $5.0 million through a November 2025 Securities Purchase Agreement by issuing 2,994,012 shares and accompanying warrants at $1.67 per share. Additionally, an Exchange Agreement on November 11, 2025, with RTW, involves exchanging convertible senior secured notes and revenue interest financing obligations for Series B convertible preferred stock, contingent on NYSE listing requirements. The company also initiated a warrant inducement offer on February 24, 2026, to lower the exercise price of existing warrants.

Why It Matters

Allurion's FDA approval for its Allurion Gastric Balloon System marks a significant milestone, opening up the lucrative U.S. market for its innovative, non-invasive weight loss solution. This could dramatically increase revenue potential and market share, challenging traditional bariatric surgery and other medical weight loss treatments. For investors, this approval, coupled with recent capital raises and debt restructuring efforts, signals a potential inflection point for growth and improved financial stability. Employees and customers stand to benefit from expanded access to a less invasive weight loss option, potentially disrupting the competitive landscape of obesity treatment.

Risk Assessment

Risk Level: medium — The company faces medium risk due to its status as an emerging growth company and the highly competitive nature of the weight loss industry. While FDA approval is a positive, the company's aggregate market value of voting and non-voting common equity held by non-affiliates was approximately $20,666,535 as of June 30, 2025, indicating a relatively small market capitalization. Furthermore, the company's reliance on future funding and the need to successfully defend litigation, as highlighted in the forward-looking statements, contribute to ongoing financial and operational uncertainties.

Analyst Insight

Investors should consider initiating a position in ALUR, given the recent FDA approval which significantly de-risks its U.S. market entry. Monitor the successful execution of its U.S. commercialization strategy and the impact of the RTW exchange agreement on its capital structure and liquidity.

Key Numbers

• $20,666,535 — Market Value of Non-Affiliate Common Equity (As of June 30, 2025, indicating a relatively small market capitalization.)
• 200,000 — Patients Treated Commercially (In over 50 countries outside the United States, demonstrating international adoption.)
• $5.0 million — Capital Raised (Through the November 2025 Securities Purchase Agreement, providing additional funding.)
• 1-for-25 — Reverse Stock Split Ratio (Effected in January 2025, impacting share count and per-share metrics.)
• 14,994,486 — Common Stock Outstanding (As of March 20, 2026, post-reverse stock split.)
• 50 — Countries of Commercial Operation (Outside the U.S., showcasing global reach prior to U.S. FDA approval.)
• 15.3 weeks — Average Balloon Residence Time (Observed for the Allurion Gastric Balloon System, indicating short-term use.)
• 30 kg/m2 and 40 kg/m2 — BMI Range for FDA Indication (Specific target patient population for the Allurion Gastric Balloon System in the U.S.)
• 2,994,012 — Shares Issued in Private Placement (Part of the November 2025 Securities Purchase Agreement, increasing share count.)
• $1.67 — Private Placement Share Price (Price per share and warrant in the November 2025 Securities Purchase Agreement.)

Key Players & Entities

• Allurion Technologies, Inc. (company) — registrant
• FDA (regulator) — granted PMA approval for Allurion Gastric Balloon System
• RTW (company) — entity exchanging notes and RIFA obligations for Series B Preferred Stock
• $5.0 million (dollar_amount) — aggregate purchase price in November 2025 Securities Purchase Agreement
• 2,994,012 (dollar_amount) — shares issued in November 2025 Private Placement
• $1.67 (dollar_amount) — purchase price per share in November 2025 Private Placement
• $20,666,535 (dollar_amount) — aggregate market value of common equity held by non-affiliates as of June 30, 2025
• February 20, 2026 (date) — date of FDA PMA approval for Allurion Gastric Balloon System
• November 11, 2025 (date) — date of November 2025 Securities Purchase Agreement and Exchange Agreement
• March 20, 2026 (date) — date for outstanding common stock count

FAQ

Risk Factors

• FDA Approval and Market Access [high — regulatory]: The company's success is heavily dependent on obtaining and maintaining regulatory approvals, such as the recent FDA PMA approval for the Allurion Gastric Balloon System (AGBS). Delays or failures in obtaining such approvals, or restrictions on the approved indications (e.g., BMI range of 30-40 kg/m2), could significantly impact market penetration and revenue. The company has treated over 200,000 patients outside the U.S., highlighting the importance of international markets prior to U.S. approval.
• Capital Raising and Liquidity [high — financial]: Allurion has a history of capital raises, including a $5.0 million Securities Purchase Agreement in November 2025. The company's ability to maintain listing on a national securities exchange and relist on the NYSE is crucial for liquidity. The Exchange Agreement with RTW and the warrant inducement offer indicate ongoing efforts to manage its financial structure and obligations.
• Product Development and Commercialization [medium — operational]: The company's core offering, the Allurion Program with its swallowable intragastric balloon, requires continuous innovation and effective commercialization. The average balloon residence time of 15.3 weeks suggests a short-term solution, necessitating ongoing patient engagement and program adherence. Successful scaling of operations in over 50 countries outside the U.S. is a prerequisite for U.S. market success.
• Litigation and Conflicts of Interest [medium — legal]: The company acknowledges the potential for litigation and the need to manage conflicts of interest among affiliates, investors, directors, and officers. Successful defense against potential litigation is a stated forward-looking concern, indicating potential legal challenges.
• Competition in Weight Loss Market [medium — market]: The weight loss market is highly competitive, with various established and emerging solutions. Allurion's Procedureless™ intragastric balloon and virtual care suite must demonstrate superior efficacy, safety, and patient satisfaction compared to traditional bariatric surgery, pharmaceuticals, and other device-based interventions.
• Reliance on Future Financing [high — financial]: The company's ability to fund its operations and growth strategies may depend on its ability to secure additional financing through equity or debt offerings. The recent capital raises and exchange agreements suggest a need for ongoing financial support to execute its business plan.

Industry Context

Allurion operates in the highly competitive and growing medical device market for obesity and weight management. Key trends include the increasing prevalence of obesity globally, a growing demand for less invasive and more convenient treatment options, and advancements in digital health and remote patient monitoring. Competitors range from pharmaceutical companies developing weight-loss drugs to other medical device manufacturers offering surgical and non-surgical interventions.

Regulatory Implications

The recent FDA PMA approval for the Allurion Gastric Balloon System is a significant milestone, enabling market entry into the U.S. However, the company must adhere to strict post-market surveillance and reporting requirements. Any adverse events or product issues could lead to regulatory scrutiny, product recalls, or restrictions, impacting sales and reputation.

What Investors Should Do

1. Monitor U.S. Market Penetration Post-FDA Approval
2. Evaluate Financial Health and Capital Needs
3. Assess Competitive Landscape and Differentiation
4. Track International Growth and Expansion

Key Dates

• 2025-01-01: Reverse Stock Split — Effected a 1-for-25 reverse stock split, impacting share count and per-share metrics, likely to meet exchange listing requirements or improve share price perception.
• 2025-11-01: Securities Purchase Agreement — Raised approximately $5.0 million by issuing shares and warrants at $1.67 per share, providing crucial funding for operations and growth initiatives.
• 2025-11-11: Exchange Agreement with RTW — Involves exchanging convertible senior secured notes and revenue interest financing obligations for Series B convertible preferred stock, contingent on NYSE listing, aimed at restructuring debt and equity.
• 2026-02-20: FDA PMA Approval for AGBS — Received FDA approval for the Allurion Gastric Balloon System for adults with a BMI between 30 kg/m2 and 40 kg/m2, opening up the significant U.S. market.
• 2026-02-24: Warrant Inducement Offer — Initiated to lower the exercise price of existing warrants, potentially encouraging their exercise and providing additional capital to the company.

Glossary

PMA

Premarket Approval. The FDA's process of reviewing the safety and effectiveness of Class III medical devices before they can be marketed in the U.S. (Crucial for the commercialization of the Allurion Gastric Balloon System in the United States.)

Procedureless™

A trademarked term by Allurion indicating a medical procedure that does not require surgery or endoscopy. (Highlights a key differentiator of the Allurion Program, emphasizing patient convenience and reduced risk.)

BMI

Body Mass Index. A measure of body fat based on height and weight that applies to adult men and women. (Defines the specific patient population for which the Allurion Gastric Balloon System has received FDA approval in the U.S.)

Securities Purchase Agreement

A contract between a company and investors outlining the terms and conditions for the sale of securities, such as shares and warrants. (Details the recent capital raise of $5.0 million, providing insight into the company's funding activities.)

Convertible Senior Secured Notes

Debt instruments that can be converted into a predetermined amount of the issuer's equity at certain times, secured by company assets. (Part of the financial restructuring involving the Exchange Agreement with RTW, impacting the company's debt and equity structure.)

Virtual Care Suite (VCS)

A collection of software tools designed for remote patient monitoring and management, often incorporating AI. (An integral part of the Allurion Program, providing ongoing support and data collection for patients undergoing weight loss treatment.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available from the provided text. The filing details recent events like the November 2025 financing and February 2026 FDA approval, suggesting a period of significant strategic and regulatory developments.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ALUR N/A Warrants to pu
• $202.50 — ase 0.056818 shares of Common Stock for $202.50 per share ALUR WS N/A Securities
• $2.43 — gistrant, based on the closing price of $2.43 per share of the Registrant's common st
• $5.0 million — gregate purchase price of approximately $5.0 million at a purchase price of $1.67 per share
• $1.67 — ely $5.0 million at a purchase price of $1.67 per share and accompanying November 202
• $6.00 — mmon Stock"), with an exercise price of $6.00 per share (the "January 2025 Warrants")
• $5.23 — Common Stock with an exercise price of $5.23 per share (the "February 2025 Warrants"
• $1.15 — rcise price of the Existing Warrants to $1.15 per share. Additionally, the Exercising
• $3.1 million — gregate gross proceeds of approximately $3.1 million from the exercise of 5 the Existing
• $1 — of Common Stock at a price per share of $1.15, will initially be exercisable follo
• $40,000 — e Company also agreed to pay Roth up to $40,000 for fees and expenses of legal counsel
• $15 million — lobal market capitalization of at least $15 million over a period of 30 consecutive trading
• $54 billion — sity treatment market is expected to be $54 billion by 2030. Moreover, according to WHO,
• $2 — pact of obesity is estimated to be over $2 trillion. We expect the rates of obes

Filing Documents

• alur-20251231.htm (10-K) — 5536KB
• alur-ex23_1.htm (EX-23.1) — 3KB
• alur-ex31_1.htm (EX-31.1) — 17KB
• alur-ex32_1.htm (EX-32.1) — 10KB
• img32663640_0.jpg (GRAPHIC) — 27KB
• img32663640_1.jpg (GRAPHIC) — 56KB
• img32663640_2.jpg (GRAPHIC) — 129KB
• img32663640_3.jpg (GRAPHIC) — 139KB
• img32663640_4.jpg (GRAPHIC) — 115KB
• img32663640_5.jpg (GRAPHIC) — 164KB
• 0001193125-26-130483.txt ( ) — 23466KB
• alur-20251231.xsd (EX-101.SCH) — 2620KB
• alur-20251231_htm.xml (XML) — 4633KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 31 Item 1B. Unresolved Staff Comments 76 Item 1C. Cybersecurity 76 Item 2.

Properties

Properties 76 Item 3.

Legal Proceedings

Legal Proceedings 77 Item 4. Mine Safety Disclosures 77 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 78 Item 6. [Reserved] 78 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 79 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 92 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 93 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 93 Item 9A.

Controls and Procedures

Controls and Procedures 93 Item 9B. Other Information 95 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 95 PART III Item 10. Directors, Executive Officers and Corporate Governance 96 Item 11.

Executive Compensation

Executive Compensation 104 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 110 Item 13. Certain Relationships and Related Transactions, and Director Independence 112 Item 14. Principal Accountant Fees and Services 118 PART IV Item 15. Exhibits and Financial Statement Schedules 119 Item 16. Form 10-K Summary 123 i Cautionary Statement Regarding Forward-Looking Statements This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, which are not purely historical, include, but are not limited to, statements regarding the plans, strategies and prospects, both business and financial, of Allurion Technologies, Inc. ("Allurion", the "Company", "we", "our", or "us"). Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors. Such risks, uncertainties and other factors could cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words "believes", "estimates", "expects", "projects", "target", "goal", "forecasts", "may", "will", "potential", "should", "would", "could", "future", "seeks", "plans", "predicts", "propose", "scheduled", "anticipates", "intends", or similar expressions. Such statements are based on the beliefs and assumptions of the management of Allurion. Although Allurion believes that its plans, intentions and expectations reflected in or sug

View Full Filing

View this 10-K filing on SEC EDGAR